title: Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema.
abstract: BACKGROUND
  Patients with severe chronic hand eczema (CHE) often respond to therapy with oral alitretinoin (9-cis retinoic acid). However, the efficacy of alitretinoin after disease relapse has not been demonstrated.
  
  
  OBJECTIVE
  To assess the efficacy and safety of a second course of oral alitretinoin in patients with severe CHE who relapsed after achieving 'clear' or 'almost clear' hands following a previous course of alitretinoin.
  
  
  METHODS
  The double-blind study included 117 patients with CHE who had responded to therapy in an earlier clinical trial and subsequently relapsed. Patients were randomized to receive their previous treatment or placebo. Treatment was alitretinoin 30 mg or 10 mg or placebo given once daily for 12-24 weeks. Response was defined as an overall Physician's Global Assessment rating of 'clear' or 'almost clear' hands at the end of therapy.
  
  
  RESULTS
  Response rates were 80% in patients retreated with 30 mg alitretinoin compared with 8% for placebo (P < 0.001). In patients retreated with 10 mg alitretinoin response rates were 48%, compared with 10% in the placebo group. Alitretinoin was well tolerated. Adverse reactions comprised typical retinoid class effects, and no late-arising side-effects were observed during this second course of treatment.
  
  
  CONCLUSIONS
  The majority of patients with CHE who previously achieved 'clear' or 'almost clear' hands following treatment with alitretinoin 30 mg per day also responded to a second course of treatment. Retreatment was well tolerated. Intermittent treatment with alitretinoin is suitable for the long-term management of CHE.
authors.affiliation: Innovaderm Research Inc., 1851 Rue Sherbrooke E., Suite 502, Montreal, QC H2K 4L5, Canada. rbissonnette@innovaderm.ca
authors.forename: R
authors.initials: R
authors.lastname: Bissonnette
authors.forename: M
authors.initials: M
authors.lastname: Worm
authors.forename: B
authors.initials: B
authors.lastname: Gerlach
authors.forename: L
authors.initials: L
authors.lastname: Guenther
authors.forename: F
authors.initials: F
authors.lastname: Cambazard
authors.forename: T
authors.initials: T
authors.lastname: Ruzicka
authors.forename: J
authors.initials: J
authors.lastname: Maares
authors.forename: T C
authors.initials: TC
authors.lastname: Brown
mesh_terms: D000284:Administration, Oral; D000077556:Alitretinoin; D002908:Chronic Disease; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006229:Hand Dermatoses / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D019233:Retreatment / Q000379:methods; D013997:Time Factors; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use*
chemical_list: D003879:Dermatologic Agents; D000077556:Alitretinoin; D014212:Tretinoin